By-production,emissions and abatement costeclimate benefit of HFC-23 in China's HCFC-22 plants

After the Kigali Amendment(KA)came into effect,HCFC-22 plants are obliged to limit HFC-23 emissions.Therefore,the study of costeffective mitigation pathways for HFC-23 is important for the sustainable implementation of KA in China and other HCFC-22 producing countries.This study constructed an inventory of HFC-23 by-production,emissions,and abatement for HCFC-22 plants in China from 2006 to 2020,and predicted the costs and climate benefits of HFC-23 abatement in China's compliance with the KA between 2021 and 2060.Results showed that HFC-23 emissions from HCFC-22 plants in China contributed about 60%of the growth in global atmospheric mole fraction of HFC-23 observed by Advanced Global Atmospheric Gases Experiment(AGAGE)from 2007 to 2020.Furthermore,China's cumulative HFC-23 abatement was about 109 kt(1613 Mt CO_(2)-eq)from 2006 to 2019,accounting for 53%of total by-production,which allowed the global atmospheric mole fraction and radiative forcing of HFC-23 in 2020 to avoid an uplift of 9.2×10^(-9)and i.7 mW m^(-2),respectively,contributing to climate change mitigation.Under the baseline of the Kigali Amendment,less emission(LE),and resource utilization(RU)scenarios,the cumulative HFC-23 abatement from 2021 to 2060 would be 683±29 kt(10,107±431 Mt CO_(2)-eq),694±29 kt(10,277±427 Mt CO_(2)-eq),and 702±29 kt(10,385±426 Mt CO_(2)-eq),respectively.The cumulative net abatement costs for the KA,LE,and RU scenarios would be(5.0±0.2)billion,(2.9±0.2)billion,and(-2.7±0.2)billion CNY(2021 prices),respectively.In the future,applying resource utilization technology to reduce HFC-23 emissions can achieve both climate and economic benefits.

Re-epithelialization resulted from prostate basal cells in canine prostatic urethra may represent the ideal healing method after two-micron laser resection of the prostate

The purpose of this study is to characterize the re-epithelialization of wound healing in canine prostatic urethra and to evaluate the effect of this re-epithelialization way after two-micron laser resection of the prostate （TmLRP）. TmLRP and partial bladder neck mucosa were performed in 15 healthy adult male crossbred canines. Wound specimens were harvested at 3 days, and 1, 2, 3, and 4 weeks after operation, respectively. The histopathologic characteristics were observed by hematoxylin and eosin staining. The expression of cytokeratin 14 （CK14）, CK5, CK18, synaptophysin （Syn）, chromogranin A （CgA）, uroplakin, transforming growth factor-β1 （TGF-β1）, and TGF-β type Ⅱ receptor in prostatic urethra wound were examined by immunohistochemistry and real-time polymerase chain reaction, respectively. Van Gieson staining was performed to determine the expression of collagen fibers in prostatic urethra and bladder neck would. The results showed that the re-epithelialization of the prostatic urethra resulted from the mobilization of proliferating epithelial cells from residual prostate tissue under the wound. The proliferating cells expressed CK14, CK5, but not CK18, Syn, and CgA and re-epithelialize expressed uroplakin since 3 weeks. There were enhanced TGF-β1 and TGF-β type Ⅱ receptor expression in proliferating cells and regenerated cells, which correlated with specific phases of re-epithelialization. Compared with the re-epithelialization of the bladder neck, re-epithelialization of canine prostatic urethra was faster, and the expression of collagen fibers was relatively low. In conclusion, re-epithelialization in canine prostatic urethra resulted from prostate basal cells after TmLRP and this re-epithelialization way may represent the ideal healing method from anatomic repair to functional recovery after injury.

Scenario analysis of hydrofluorocarbons emission reduction in China's mobile air-conditioning sector

With the Kigali Amendment(KA)coming into effect in China,the control of hydrofuorocarbons(HFCs)emissions has become more imperative.The mobile air-conditioning(MAC)sector is one of the important HFCs consumer sectors,and therefore studying its feasible mitigation paths and costs is of great significance to Chinas successful implementation of KA.This study used the bottom-up method with updated emission factors to re-evaluate the emission inventory of HFCs from the MAC sector in China from 2005 to 2020.The average annual growth rate of HFCs consumption in the MAC sector is 9.8%,and HFCs emissions have increased from 5.8(5.3-6.2)kt in 2005 to 22.2(20.6-23.8)kt in 2020,with an average annual growth rate of 8.8%.Using the Gompertz model combined with the Weibull function of vehicle survival rate,the ownership and new registrations of internal combustion engine vehicles(ICEVs)and electric vehicles(EVs)in China are predicted.The ownership of ICEVs and EVs is projected to be 310 million and 91 million in 2030,respectively and 2 million and 641 million in 2060,respectively.HFCs emissions in the MAC sector would reach 59.8(55.3-64.3)kt(80.093.0 Mt CO_(2-eq))in 2060 if without any control measure.To implement the KA,the cumulative of 1.6 Gt CO_(2-eq) emissions would be reduced.Under the other two accelerated mitigation scenarios,the MAC sector's HFCs will reach their emissions peak in 2028 and 2025 and achieve zero emissions in 2050 and 2046,respectively.Under the accelerated mitigation with recovery scenario,the cumulative emissions are only 15.0%of the business as usual(BAU)scenario.Using HFO-1234yf as the substitute,the unit abatement cost of the MAC sector is 27.3-37.4 USD _(t)^(-1)CO_(2-eq).

Low deceleration capacity is associated with higher stroke risk in patients with paroxysmal atrial fibrillation

Background: Deceleration capacity (DC) is a non-invasive marker for cardiac autonomic dysfunction;however, few studies have shown that the influence factors of cardiac autonomic dysfunction and the correlations between DC and stroke risk in paroxysmal atrial fibrillation (AF). We aimed to explore the influencing factors of abnormal DC and the relationships between DC and stroke risk in patients with paroxysmal AF. Methods: The study included hospitalized paroxysmal AF patients with DC measurements derived from 24-h Holter electrocardiography recordings taken between August 2015 and June 2016. Multivariable regression analysis was performed to evaluate the associations between correlated variables and abnormal DC values. The relationship between DC and ischemic stroke risk scores in patients with paroxysmal AF was analyzed. Results: We studied 259 hospitalized patients with paroxysmal AF (143 [55.2%] male, mean age 66.4 ± 12.0 years);38 patients of them showed abnormal DC values. In the univariate analysis, age, hypertension, heart failure, and previous stroke/transient ischemic attack (TIA) were significantly associated with abnormal DC values. Among these factors, a history of previous stroke/TIA (odds ratio = 2.861, 95% confidence interval: 1.356–6.039) were independently associated with abnormal DC values in patients with paroxysmal AF. The abnormal DC group showed a higher stroke risk with the score of congestive heart failure, hypertension, age >75 years, diabetes mellitus, previous stroke and TIA (CHADS2)(2.25 ± 1.48 vs. 1.40 ± 1.34, t =-4.907, P = 0.001) and CHA2DS2-vascular disease, age 65–74 years and female category (VASc)(3.76 ± 1.95 vs. 2.71 ± 1.87, t =-4.847, P = 0.001) scores. Correlation analysis showed that DC was negatively correlated with CHADS2 scores (r =-0.290, P < 0.001) and CHA2DS2-VASc scores (r =-0.263, P > 0.001). Conclusions: Lower DC is closely associated with previous stroke/TIA, and is also correlated negatively with higher stroke risk scores in patients with paroxysmal AF. It could be a potential indicator of stroke risk in paroxysmal AF patients.

Evaluation of Safety and Efficacy of Qinming8631 DR Implantable Cardiac Pacemaker in Chinese Patients： A Prospective, Multicenter, Randomized Controlled Trial of the First Domestically Developed Pacemaker of China

Background：High cost of imported pacemakers is a main obstacle for Chinese patients suffering from bradyarrhythmia,and a domestically developed pacemaker will help lower the burden.This study aimed to evaluate the safety and efficacy ofQinming8631 DR （Qinming Medical,Baoji,China）,the first domestically developed dual-chamber pacemaker of China,compared with a commercially available pacemaker Talos DR （Biotronik,Berlin,Germany） in Chinese patients.Methods：A prospective randomized trial was conducted at 14 centers in China.Participants were randomized into trial （Qinming8631 DR） and control （Talos DR） groups.Parameters of the pacing systems were collected immediately after device implantation and during follow-ups.The effective pacing rate at 6-month follow-up was recorded as the primary end point.Electrical properties,magnet response,single-and double-pole polarity conversion,rate response function,and adverse events of the pacing system were analyzed.The Cochran-Mantel-Haenszel Chi-square test,paired t-test,and Wilcoxon signed-rank test were used for measuring primary qualitative outcomes and comparing normally and abnormally distributed measurement data.Results：A total of 225 patients with a diagnosis ofbradyarrhythmia and eligible for this study were randomly enrolled into the trial （n =113） and control （n =112） groups.They underwent successful pacemaker implantation with acceptable postoperative pacing threshold and sensitivity.Effective pacing rates of trial and control groups were comparable both in the full analysis set and the per protocol set （81.4% vs.79.5%,P =0.712 and 95.4% vs.89.5%,P =0.143,respectively）.In both data sets,noninferiority of the trial group was above the predefined noninferiority limit（-9.5%）.Conclusions：This study established the noninferiority ofQinming8631 DR to Talos DR.The safety and efficacy ofQinming8631 DR pacemaker were comparable to those of Talos DR in treating patients with cardiac bradyarrhythmia.